Spectrum Management Group’s Sage Therapeutics SAGE Stock Holding History

Spectrum Management Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4	Closed	–	–	386
2017 Q3	$0	Buy	+4	New	+$314	﹤0.01%	438

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Spectrum Management Group's SAGE Position: Q4 2017 in Review

Spectrum Management Group sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 4 shares.

Spectrum Management Group first reported a position in SAGE in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

Spectrum Management Group reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
Spectrum Management Group sold 4 Sage Therapeutics shares in Q4 2017.
Spectrum Management Group first reported a position in Sage Therapeutics in Q3 2017 and held it in 1 quarter.
Spectrum Management Group's Sage Therapeutics position peaked at $0 in Q3 2017.
224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Spectrum Management Group's 13F filing for Q4 2017, filed 7 Feb 2018.